

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
29 October 2020 (29.10.2020)



(10) International Publication Number
WO 2020/219922 A1

(51) International Patent Classification:

A61K 39/395 (2006.01) C07K 16/46 (2006.01)
C07K 16/18 (2006.01)

(21) International Application Number:

PCT/US2020/029876

(22) International Filing Date:

24 April 2020 (24.04.2020)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/837,853 24 April 2019 (24.04.2019) US
62/837,833 24 April 2019 (24.04.2019) US

(71) Applicants: **THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA** [US/US]; 3600 Civic Center Boulevard, 9th Floor, Philadelphia, PA 19104 (US). **KIRA PHARMACEUTICALS (US) LLC** [US/US]; 164 Pleasant Street, Arlington, MA 02476 (US).

(72) Inventors: **SONG, Wenchao**; 213 Cornell Drive, Bryn Mawr, PA 19010 (US). **MIWA, Takashi**; 191 Presidential Blvd., Unit 323, Bala Cynwyd, PA 19004 (US). **GUL-LIPALLI, Damodar**; 4007 Woodland Avenue, Apt. 13, Philadelphia, PA 19104 (US). **SATO, Sayaka**; 2130 Locust Street, Apt. #A1, Philadelphia, PA 19103 (US). **TSUI, Ping**; 15801 Chagall Terrace, North Potomac, MD 20878 (US). **ZHU, Yingjie**; 64 Scotch Cap Road Unit 125, Quaker Hill, CT 06375 (US). **ZHU, Xihua**; 95 Airport Road, Nanshan Weila 1-612, Wuzhong District, Suzhou, 215000 (CN).

(74) Agent: **HAAS, Dennis, L.** et al.; Riverside Law, LLP, Glenhardie Corporate Center, 1285 Drummers Lane, Suite 202, Wayne, PA 19087 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,

UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))

WO 2020/219922 A1

(54) Title: BI-FUNCTIONAL HUMANIZED ANTI-C5 ANTIBODIES AND FACTOR H FUSION PROTEINS AND USES THEREOF

(57) Abstract: This invention relates to inhibition of the complement signaling using an anti-C5 antibody or fusion protein thereof. Specifically, the invention relates to methods of treating a complement-mediated disease or complement-mediated disorder in an individual by contacting the individual with an anti-C5 antibody fusion protein thereof.